A chemical biology approach identifies a beta 2 adrenergic receptor (b2AR) agonist ARA-211 (Pirbuterol), which causes apoptosis and human tumor regression in animal models. b2AR stimulation of cAMP formation and protein kinase A (PKA) activation leads to Raf-1 (but not B-Raf) kinase inactivation, inhibition of Mek-1 kinase and decreased phospho-extracellular signal-regulated kinase (Erk)1/2 levels. ARA-211 inhibition of the Raf/ Mek/Erk1/2 pathway is mediated by PKA and not exchange protein activated by cAMP (EPAC). ARA-211 is selective and suppresses P-Erk1/2 but not P-JNK, P-p38, P-Akt or P-STAT3 levels. b2AR stimulation results in inhibition of anchorage-dependent and -independent growth, induction of apoptosis in vitro and tumor regression in vivo. b2AR antagonists and constitutively active Mek-1 rescue from the effects of ARA-211, demonstrating that b2AR stimulation and Mek kinase inhibition are required for ARA-211 antitumor activity. Furthermore, suppression of growth occurs only in human tumors where ARA-211 induces cAMP formation and decreases P-Erk1/2 levels. Thus, b2AR stimulation results in significant suppression of malignant transformation in cancers where it blocks the Raf-1/Mek-1/Erk1/2 pathway by a cAMP-dependent activation of PKA but not EPAC.
Introduction
Malignant transformation of normal cells to cancer cells requires the acquisition of several oncogenic traits such as uncontrolled cell division, resistance to programmed cell death (apoptosis), invasion and angiogenesis (Hanahan and Weinberg, 2000) . These malignant transformation traits are believed to be the consequence of the accumulation of genetic alterations that result in deregulated signal transduction circuits. Such genetic alterations can simply be point mutations that result in constitutive activation of key signal transducers such as Ras, a GTP/GDP binding GTPase that contributes to 30% of all human cancers (Bos, 1989) . Alternatively, these alterations can involve entire genes such as the receptor tyrosine kinases, epidermal growth factor receptor and erythroblastic leukemia viral oncogene homolog 2 (ErbB2) that are found overexpressed in many major human cancers, including breast and lung tumors (Slamon et al., 1987) . Often such genetic alterations result in constitutive activation of common downstream signal transduction pathways such as the mitogen-activated protein (MAP) kinase cascades of several serine/threonine kinases, including Raf-1, Mek-1, extracellular signal-regulated kinase (Erk)1/2, p38 and Jun kinase (JNK) (Hagemann and Blank, 2001; Johnson and Lapadat, 2002) . Other pathways involved in uncontrolled proliferation, apoptosis, invasion and angiogenesis also include those mediated by the signal transducer and activator of transcription STAT3 and the serine/threonine kinase Akt (Alvarez and Frank, 2004; Fresno Vara et al., 2004) . Not only have these oncogenic and tumor survival pathways been found constitutively activated in the great majority of human cancers, but also their hyperactivation has been associated with poor prognosis and resistance to chemotherapy in cancer patients (Slamon et al., 1987) . This has prompted drug discovery efforts targeting receptor tyrosine kinases, Ras, Raf-1, Mek, Akt and STAT3 to thwart aberrant signal transduction pathways in tumor cells (Sebolt-Leopold et al., 1999; Sebolt-Leopold, 2000; Weinstein-Oppenheimer et al., 2000; Blaskovich et al., 2003; Redell and Tweardy, 2005) . For example, inhibitors of receptor tyrosine kinases, Ras, Raf-1 and Mek-1 have all been identified and are at various stages of development (English and Cobb, 2002; Hao and Rowinsky, 2002) . Some, like the epidermal growth factor receptor (EGFR) kinase inhibitors, Iressa and Tarceva, were recently approved by the Food and Drug Administration for the treatment of patients with lung cancer (Johnson et al., 2005) .
In normal cells, the regulation of the MAP kinase pathway is complex. Although it is well established that the activation of Erk kinases is regulated by receptor tyrosine kinases such as EGFR and platelet-derived growth factor receptor (PDGFR) via activation of Ras, which in turn activates the Raf-1/Mek/Erk1/2 cascade (Hagemann and Blank, 2001; Johnson and Lapadat, 2002) , more recently, adrenergic receptor (AR) stimulation of cAMP has also been shown to regulate the activation of Erk1/2 in normal cells (reviewed in Carman and Benovic, 1998; Cox et al., 2000; Enserink et al., 2002; Stork and Schmitt, 2002) . For example, in some normal cells such as cardiac myocytes and bone cells, cAMP was shown to activate Erk1/2, whereas in others such as adipocytes and endothelial cells, it was shown to inhibit Erk1/2 activation (Vossler et al., 1997; Steinberg, 2000; Stork, 2001, 2002; Troadec et al., 2002) . In tumor cells, however, little is known about AR regulation of Erk1/2 activation. In this manuscript, we have demonstrated that stimulation of the beta2 adrenergic receptor (b2AR) induces significant tumor growth suppression and tumor regression in human cancers where this stimulation results in the inactivation of the Raf-1/Mek-1/Erk1/2 pathway by a cAMP-dependent activation of protein kinase A (PKA), but not by the Rap1 guanine exchange factor exchange protein activated by cAMP (EPAC).
Results
Many common genetic alterations in human cancers result in the hyperactivation of the kinase Mek-1, leading to constitutively phosphorylated Erk1/2 (Hagemann and Blank, 2001; Johnson and Lapadat, 2002) . Because aberrant activation of the Mek-1/Erk1/2 pathway has been implicated in oncogenesis and tumor survival, we sought to identify molecules that thwart this pathway. To this end, we first used a chemical biology approach by screening a 2000 small molecule compound library (NCI diversity set, http://dtp.nci.nih.gov/) from the National Cancer Institute for pharmacological agents, capable of suppressing the high levels of PErk1/2 in the human breast cancer cell line MDA-MB-231. Treatment of MDA-MB-231 cells with compounds from the NCI diversity set (96-well plate assay (25 plates total), one compound per well -see Figure 1a ) and subsequently processing the plates for a cytoblot, using an antibody specific for P-Erk1/2, resulted in several compounds that suppress P-Erk1/2 levels. One of these, ARA-211 ( Figure 1a ) suppressed potently the levels of P-Erk1/2 without affecting the levels of total Erk1/2 (Figure 1b) .
ARA-211 also suppressed P-Mek-1 levels but not P-Raf-1, P-JNK, P-p38, P-Akt or P-STAT3 (Figure 1b) . These results demonstrated that ARA-211 is selective for disrupting the Mek-1/Erk1/2, but not other oncogenic and tumor survival pathways. The fact that ARA-211 suppressed the levels of P-Mek-1 and P-Erk1/2 suggested that it might be a Raf-1 kinase inhibitor. In vitro incubation of Raf-1 and Mek-1, immunoprecipitated from MDA-MB-231 cells with ARA-211, did not inhibit Raf-1 and Mek-1 kinase activities ( Figure 1c ). As expected, the Raf-1 kinase inhibitor (Rki, EMD Biosciences, San Diego, CA, USA) and the Mek-1 inhibitor (U-0126, EMD Biosciences, San Diego, CA, USA) blocked Raf-1 and Mek-1 kinase activities in vitro, respectively (Figure 1c) . In contrast to the in vitro studies, Raf-1 and Mek-1 kinase activities were blocked by ARA-211 when intact MDA-MB-231 cells were first treated with ARA-211 before cell lysis and immunoprecipitation of Raf-1 and Mek-1 (Figure 1d ). As expected, only Rki but not U-0126 inhibited Raf-1 kinase, whereas both Rki and U-0126 inhibited Mek-1 kinase when whole cells were treated. In contrast, to the effects on Raf-1 kinase activity, B-Raf kinase activity was not affected upon stimulation of cells with ARA-211 (data not shown).
Because ARA-211 inhibits Raf-1 and Mek-1 kinase activities when intact cells are treated, but not in vitro, suggested that the target for this compound is upstream of Raf-1 kinase. An ACS chemical library search identified ARA-211 as Pirbuterol, a b2AR agonist. To demonstrate that ARA-211 acts as a b2AR agonist in MDA-MB-231 cells, and that this results in blockade of the Raf/Mek/Erk pathway, we treated these cells with ARA-211 and first showed that this compound induced the formation of cAMP (Figure 2a ). We then determined that ARA-211 is highly selective for b2ARs by determining that only b2 but not b1, a1 or a2 receptor antagonists block the ability of ARA-211 to induce cAMP formation (Figure 2a) . Furthermore, we used isopreterenol, a b-specific AR agonist, and showed that it also stimulates the formation of cAMP and decreases the levels of P-Erk1/2 (data not shown). Finally, treatment of MDA-MB-231 cells with a b1 selective agonist, dobutamine and a b3 selective agonist, CI316, 243, did not inhibit P-Erk1/2 levels (data not shown).
We then demonstrated that the ability of ARA-211 to disrupt the Raf-1/Mek-1/Erk1/2 pathway requires its ability to stimulate the b2 adrenergic pathway by demonstrating that the b2AR antagonists prevented ARA-211 from suppressing P-Erk1/2 levels ( Figure 2b ). Furthermore, we used the adenylyl cyclase activator forskolin to directly induce cAMP production, and determined that forskolin alone can inhibit P-Erk1/2 in MDA-MB-231 cells (Figure 2c ). Taken together, these data demonstrate that ARA-211 is a b2-selective AR agonist that suppresses P-Erk1/2 by increasing cAMP levels.
Figures 1 and 2 demonstrated that ARA-211 stimulates the production of cAMP which, in turn, suppresses the Raf/Mek-1/Erk1/2 pathway. We next examined whether cAMP suppresses the P-Erk1/2 levels by activating PKA or by activating the Rap1 guanine exchange factor EPAC. To this end, we treated MDA-MB-231 cells either with the EPAC activator 8-CPT-2 0 -O-Me-cAMP or the PKA kinase inhibitor H-89. Figure 3a shows that treatment with the EPAC activator did not affect P-Erk1/2 levels. In contrast, treatment with the PKA inhibitor prevented ARA-211 from suppressing the levels of P-Erk1/2 (Figure 3b ). We next determined if ARA-211 is able to activate PKA. Figure 3c shows that ARA-211 treatment of MDA-MB-231 cells activated PKA kinase activity and that the PKA inhibitor H-89 prevented ARA-211 from activating PKA.
Figures 1-3 demonstrated that stimulation of the b2AR with ARA-211 suppresses the Raf-1/Mek-1/Erk1/ 2 pathway by a cAMP-dependent activation of PKA but not EPAC. We next determined whether activation of the b2AR and inhibition of the Raf-1/Mek-1/Erk1/2 pathway results in inhibition of tumor cell growth and survival of human cancer cells. To this end, we first used a panel of six human cancer cell lines, including three where ARA-211 inhibits P-Erk1/2 levels (MDA-MB-231 (breast), SF-539 central nervous system (CNS) and ACHN (renal)), and three where it did not (A-549 (lung), hematopoietic stem cell transplantation (HCT)-116 (colon) and SNB-19 (CNS)). Figure 4a and Table 1 show that P-Erk1/2 levels were suppressed only in the human cancer cell lines where ARA-211 induced cAMP production. Furthermore, ARA-211 potently inhibited anchorage-dependent and -independent growth, and induced apoptosis in cell lines where it stimulated the b2AR and inhibited P-Erk1/2, but not in cell lines in which ARA-211 did not induce cAMP and decreased P-ERK1/2 levels ( Figure 4a and Table 1 ). Similar data were obtained with another b selective AR agonist isopreterenol (data not shown). Forskolin, which activates adenylyl cyclase directly and produces cAMP, inhibited the growth of MDA-MB-231 cells (Figure 4b ), further demonstrating the importance of cAMP in ARA-211 inhibition of tumor cell growth. To further demonstrate that the ability of ARA-211 to decrease P-Erk1/2 levels and to inhibit tumor cell growth requires stimulation of the b2AR, we showed that b2AR antagonists rescued human cancer cells from ARA-211 inhibition of tumor cell growth and suppression of Erk1/2 phosphorylation ( Figure 4c) . The above data clearly demonstrated that the ability of ARA-211 to disrupt the Raf-1/Mek-1/Erk1/2 pathway and to inhibit tumor cell growth and survival depends on its ability to stimulate the b2AR and produce cAMP. However, the ability of ARA-211 to inhibit tumor cell growth could be due to its ability to affect cellular events other than those leading to decreased P-Erk1/2. Therefore, we next determined whether the inhibition of tumor cell growth by ARA-211 requires its ability to inhibit the Raf-1/Mek-1/Erk1/ 2 pathway. We reasoned that if suppression of Raf-1 and Mek-1 is critical to ARA-211 inhibition of tumor growth, then ectopically expressing constitutively active Mek-1 would rescue human cancer cells from the effects of ARA-211. Figure 4d shows that MDA-MB-231 cells that ectopically express constitutively active Mek-1 are resistant to ARA-211 inhibition of P-Erk1/2 and inhibition of tumor cell growth.
The ability of ARA-211 to inhibit tumor cell growth and induce apoptosis in cultured cells in a b2AR and Mek-1-dependent manner suggested that ARA-211 might induce tumor regression in human cancers where it can block the Raf-1/Mek-1/Erk1/2 pathway. Therefore, we determined the ability of ARA-211 to interfere with the growth and progression of nude mice xenografts of several human cancer cells. Stimulation of the b2AR results in tumor growth inhibition AE Carie and SM Sebti tumor regression, the mice were taken off of the treatment regiment and monitored for tumor growth for an additional 3 weeks, during which none of the tumors regrew and remained undetectable (data not shown). Similarly, the growth of ACHN renal tumors was inhibited when the mice were treated i.p. with ARA-211 (75 mpk/day), and tumor growth was blocked at 200 mpk/day (Figure 5b , 200 mpk started at day 12 (see m). Immunohistochemistry (IHC) analysis of tumors from MDA-MB-231 tumor xenografts, treated with ARA-211 (75 mpk/day i.p.) or vehicle, were analysed for inhibition of P-Erk1/2, inhibition of proliferation (Ki-67) and induction of apoptosis (TdTmediated dUTP nick end labeling assay (TUNEL)). Figure 6a shows that treatment of mice with ARA-211 (75 mpk/day) inhibited tumor growth by 63%. (The dose of 75 mpk/day was purposefully used to only partially inhibit tumor growth so that enough tissue could be collected for analysis.) Tumors from ARA-211-treated mice had a significant decrease in cells staining positive for P-Erk1/2 (62%, P ¼ 0.02) and Ki-67 (38%, P ¼ 0.007) along with a significant increase in cells staining positive for TUNEL (sixfold, P ¼ 0.0045).
Discussion
In this manuscript, a chemical biology approach was used to interrogate aberrant signal transduction circuits in human cancer cells about the importance of the b2AR in regulating cell division and tumor survival. Our studies clearly demonstrated that activation of the b2AR by ARA-211 results in inhibition of anchoragedependent and -independent tumor cell growth, as well as induction of apoptosis and tumor regression, in human tumors where stimulation of the b2AR results in blockade of the Raf-1/Mek-1/Erk1/2 pathway. The mechanism by which ARA-211 inhibits the Raf-1/Mek-1/ERK1/2 involves a cAMP-dependent PKA, but not EPAC activation. Furthermore, ARA-211 inhibition of tumor cell growth is rescued by b2AR antagonists, suggesting that growth inhibition requires b2AR signaling. This is consistent with other studies that showed that isoprenaline, cholera toxin, forskolin and 8-bromocAMP inhibit DNA synthesis and cell growth (Veber et al., 1994; . Increases in cAMP levels have also been shown to inhibit mitosis and MMPs expression in MDA-MB-231 cells (Yu et al., 1998; .
Our studies also demonstrated that constitutively active Mek-1 rescues from ARA-211 inhibition of tumor cell growth, suggesting that ARA-211 must inhibit Raf-1/ Mek-1/Erk1/2 to induce its antitumorigenesis effects. This is an important finding as a large number of human cancers harbor genetic alterations that ultimately result in hyperactivation of the Raf-1/Mek-1/Erk1/2 pathway. For example, it is estimated that 30% of all human cancers contain Ras mutations that lead to hyperactivation of this pathway (Bos, 1989) . Similarly, a great majority of human cancers overexpress or contain constitutively activated receptor and non-receptor tyrosine kinases and/or growth factor autocrine loops that also result in hyperactivation of the Raf-1/Mek-1/Erk1/2. (Di Marco et al., 1989; Fleming et al., 1992; Watanabe et al., 1996; Graells et al., 2004) . More importantly, hyperactivation of this pathway is critical to the growth and survival of human tumors (Sebolt-Leopold et al., 1999) . Finally, thwarting this pathway in human cancers may result in great benefits in the treatment of cancer ARA-211 suppresses P-Erk1/2 levels, inhibits tumor cell growth and induces apoptosis in human xenografts in nude mice. MDA-MB-231 cells were implanted under mammary fat pads and the mice treated with vehicle (') or ARA-211 (J, 75 mpk/day) as described under Figure 5 , tumors removed on day 12 and processed for P-Erk1/2 levels (IHC), apoptosis (TUNEL) and proliferation (Ki-67) as described under Materials and methods. Pictures represent 1/100 of the total slide area analysed for one of the three samples per treatment group.
Stimulation of the b2AR results in tumor growth inhibition AE Carie and SM Sebti patients as the genetic aberrations (i.e., Ras mutations, EGF-R and ErbB2 over expression) that result in hyperactivation of the Raf-1/Mek-1/Erk1/2 pathway have all been associated with poor prognosis, resistance to therapy and shortened patient life (Slamon et al., 1987; Weldon et al., 2002; Jin et al., 2003) . Using b2 stimulation to cause tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway is a novel and powerful approach that could have a widespread use in cancer therapy. Indeed, tumors activate this pathway with a broad spectrum of growth factors/ cytokines and their receptors. For example, many growth factors such as EGF, PDGF, fibroblast growth factor, vascular endothelial growth factor, insulin growth factor-1, heregulin and others all activate this pathway (Di Marco et al., 1989; Strobl et al., 1995; Dhillon and Kolch, 2002) . Therefore, tumors that express two or more of these growth factors may require a cocktail of anticancer drugs. In contrast, b2AR stimulation will block activation of the Raf-1/Mek-1/Erk1/2 pathway when it is driven by several growth factors as they all require Mek to activate Erk1/2 (Graves et al., 1993; Sevetson et al., 1993; Wu et al., 1993; Sebolt-Leopold, 2000; Dumaz and Marais, 2005) . For example, we have shown that growth factor (i.e., EGF) stimulation of P-Erk1/2 is blocked by ARA-211 in MDA-MB-231 cells (data not shown).
This approach, however, is limited to those human tumors that express the b2AR and to where the stimulation of this receptor results in blockade of Raf-1/ Mek-1/Erk1/2. In normal cells, it has been shown that adrenergic stimulation can either stimulate or inhibit P-Erk1/2 and proliferation (Sevetson et al., 1993; Maudsley et al., 2000; Stork and Schmitt, 2002) . However, in tumor cells, it is not known if stimulation of the b2AR can stimulate tumorigenesis. In some normal cells expressing B-Raf, b2ARs stimulate Erk1/2 by activating B-Raf which, in turn, activates Mek-1 (Erhardt et al., 1995; Vossler et al., 1997) whereas in other normal cells, b2ARs inactivate Erk1/2 by blocking Raf-1 (Hafner et al., 1994; Stork, 2001, 2002; Tortora and Ciardiello, 2002) . Therefore, b2ARs may also inhibit or stimulate Erk1/2 and proliferation in tumors, and this may depend on the expression levels of not only the b2AR but also Raf-1 and/or B-Raf.
To translate these important results to clinically relevant findings, fresh human tumor biopsies should be used to determine the effects of b2AR stimulation on P-Erk1/2 levels in b2AR-expressing tumors as well as to determine if the ability of b2AR stimulation to inhibit proliferation and induce apoptosis depends on the ratio of C-Raf to B-Raf expression. The fact that ARA-211 (pirbuterol) has previously been used orally and locally (Steen et al., 1974; Moore et al., 1978; Grassi et al., 1986) in humans to evaluate its potential as an antiasthmatic and as treatment for congestive heart failure will facilitate its testing as an anticancer drug in a hypothesis-driven clinical trial with patients where b2AR stimulation is predicted to block Raf-1/Mek-1/ Erk1/2.
Materials and methods

Cell lines and transfections
All cell lines used were obtained from American Type Tissue Collection (Manassas, VA, USA), or from the DCTD Tumor Repository (Frederick, MD, USA). DNA transfections were carried out using TransIT-LT1 transfection reagent (Takara Mirus, Madison, WI, USA) according to the manufacturer's protocol. Briefly, LT1 was preincubated in 200 ml in Opti-MEM (Invitrogen, Carlsbad, CA, USA) before addition of plasmid (2 mg of pFC-MEKK plasmid, Stratagene, La Jolla, CA, USA). The mixture was then added to 4 Â 10 5 MDA-MB-231 cells grown to approximately 70% confluency and incubated at 371C for 48 h. At that time, cells were treated with either dimethyl sulfoxide (DMSO) or ARA-211 (10 mM) for 48 h and assayed for proliferation via Alamar Blue and Western blot analysis as described below.
Cytoblot screening for small molecules that decrease phospho-Erk1/2 MDA-MB-231 cells (25 000 cells/well) were plated into sterile, white opaque, 96-well plates, allowed to attach overnight, and treated for 1 h in the presence of either vehicle control, 20 mM PD-98059 (EMD Biosciences), or 10 mM of NCI Diversity Set of 2000 compounds (one compound/well) (http://dtp.nci.nih. gov/) as described by us (Blaskovich et al., 2003) . Cells were washed, fixed, permeabilized, re-washed and rocked overnight at 41C with anti-phospho-p44/42 MAPK and anti-Rabbit IgG secondary antibody. The plates were washed and chemiluminescence reagent added, and the X-ray film was then directly placed on top of the plates.
Western blotting
This was carried out exactly as described previously by us (Blaskovich et al., 2003) . The following antibodies were used: phospho-STAT3, phospho-AKT, phospho-c-Raf, phosphoMek and phospho-p44/p42 MAPK antibodies (Cell Signaling Technology, Danvers, MA, USA). Cells treated with ARA-211, 8CPT-2 0 -O-Me-cAMP, H89 and Forskolin to determine their effects on P-Erk1/2 and other signaling events by Western blot were treated for 1 h at varying doses. Pretreatment with H89 was performed for 15 min followed by 45 min of ARA-211 treatment.
In vitro kinase assays MDA-MB-231 cells (2 Â 10 6 ) were lysed for 30 min at 41C in radioimmunoprecipitation assay (RIPA)-150 buffer (10 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM ethylene diamine tetracetic acid (EDTA), 1% Triton X-100, 1% sodium dodecyl sulfate (SDS), 100 mM sodium orthovanadate, 1 mM aprotinin, 10 mM leupeptin, 10 mM antipain). The lysates were rocked overnight with 10 mg of either c-Raf or MEK antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA, USA). A portion of 25 ml of protein A/G PLUS agarose beads (Santa Cruz Biotechnology) was then added and rocked for 4 h at 41C. Beads were resuspended in 30 ml kinase buffer (30 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulphonic acid, pH 7.5, 7 mM MnCl 2 , 5mM MgCl 2 , 1mM dithiothreitol and 15 mM adenosine triphosphate (ATP) with either 10 mM U-0126 (EMD Biosciences) ARA-211, Raf kinase inhibitor (EMD Biosciences) or DMSO vehicle control. A portion of 0.5 mg MEK-1 or ERK-2 peptide substrate (Upstate Biotechnologies, Lake Placid, NY, USA) was added, followed by 20 mCi [g-32 P]-ATP. Samples were incubated at room temperature for 30 min, the reaction terminated by the addition of 30 ml 4 Â SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer and boiled at 1001C for 5 min. Samples were run on 10% SDS-PAGE gels, dried and the results visualized by autoradiography.
In vivo kinase assay Intact MDA-MB-231 cells (2 Â 10 6 ) were treated either with vehicle control (DMSO), 10 mM U-0126, 10 mM Raf kinase inhibitor or 10 mM ARA-211. Samples were then processed for kinase assays as described above.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide thiazolyl blue assay Assays were carried out exactly as described previously by us (Sebti et al., 1991) .
Alamar Blue proliferation assay For proliferation assays using exogenous constitutively activated MEK or the b2AR antagonist ICI-118.551, Alamar Blue metabolism assay was used to determine cell viability according to the manufacturer's protocol (Biosource, Camarillo, CA, USA). Briefly, cells were treated and grown as described above; Alamar Blue was added to the media at a 1:10 dilution and incubated for 3 h. Media/Alamar Blue was removed from the cells and aliquoted into 96-well plates (100 ml per well), and fluorescence read on a Wallac Victor 2 plate reader at excitation 540 nM and emission 615 nM.
Soft agar assay
Anchorage-independent growth assays were performed as described previously (Lerner et al., 1997) .
Apoptosis assay
Cells (1 Â 10 5 ) were plated in 60 mm dishes and treated with various doses of ARA-211 or vehicle for 48 h. Apoptosis was analysed using the Cell Death Detection ELISA (Roche, Indianapolis, IN, USA) measuring cytoplasmic histoneassociated mono-and oligonucleosome DNA fragments.
Total cellular cAMP measurement Two thousand cells were plated into each well of a 96-well plate. The next day cells were treated with increasing concentrations of ARA-211 or with vehicle for 1 h. Alternatively, MDA-MB-231 cells were pretreated with antagonists to the a1 (Prazosin, Sigma), a2 (Yohimbine, Sigma), b1 (Metoprolol, Sigma-Aldrich, St Louis, MO, USA), and b2 (ICI 118.551, Sigma) ARs at 100 nM for 15 min followed by treatment with 10 mM ARA-211 for 45 min. The measurement of total cellular cAMP was carried out using a cAMP Biotrak Enzyme immuno assay system (Amersham Biosciences, Piscataway, NJ, USA), according to the manufacturer's protocol.
PKA kinase assay Cells were plated (5 Â 10 6 ) into 100 mm dishes and treated the next day with ARA-211, H-89 (EMD Biosciences) or vehicle for 1 h. When pretreating cells, H89 was incubated for 15 min following ARA-211 treatment for 45 min. PKA kinase assays were performed with the SignaTECT cAMP-Dependent PKA Assay System (Promega, Madison, WI, USA), according to the manufacturer's protocol.
Antitumor activity in nude mouse xenograft model Female athymic nude (nu/nu) mice, 5-6 weeks old, were purchased from Charles River (Wilmington, MA, USA) and allowed to acclimate in the animal facility for 1 week. After harvesting, A-549, SNB-19, ACHN and HCT-116 cells were resuspended in sterile PBS and injected subcutaneously (s.c.) into the right and left flanks (10 Â 10 6 cells per flank) of the mice as described previously (Sun et al., 2005) . For MDA-MB-231, cells were harvested and resuspended in phosphatebuffered saline (PBS) (10 Â 10 6 cells per 50 ml) and an equal volume of Matrigel (BD Biosciences, San Jose, CA, USA). MDA-MB-231 (100 ml) cells in PBS/Matrigel were injected s.c. into the mammary fat pads between the second and third nipples on each side of the mice. Once the tumors reached approximately 200-300 mm 3 , the mice were randomized and treated i.p. with 0.1 ml vehicle (PBS) or ARA-211. Each treatment group consisted of five mice (two tumors per mouse, a total of 10 tumors). The tumor volumes were determined by measuring the length (l) and width (w), and by calculating the volume (V ¼ w 2 l/2). Statistical significance between the control and treated animals was determined using a Student's t-test.
IHC and slide quantitation
Mice were euthanized and the tumors were fixed in 10% buffered formalin. Three tumors per treatment group were then prepared and stained for proliferation marker Ki-67, apoptosis by TUNEL and phosphor-Erk1/2 as described previously . The Ariol SL-50 automated image analysis system (Applied Imaging, Santa Clara, CA, USA) was used for quantitation of each slide, as described previously (Jiang et al., 2004) . Each slide analysed consisted of 54 000-160 000 cells analysed depending on the size of the tumor when resected. Significance of the quantitation was analysed by a two-tailed Student's t-test.
